Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer.
- Author:
Sung Ja AHN
1
;
Young Chul KIM
;
Kyu Sik KIM
;
Kyung Ok PARK
;
Woong Ki CHUNG
;
Taek Keun NAM
;
Byung Sik NAH
;
Ju Young SONG
;
Mi Sun YOON
Author Information
1. Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea. ahnsja@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Radiotherapy;
Chemotherapy;
Non-small cell lung cancer
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Drug Therapy*;
Female;
Humans;
Male;
Radiotherapy;
Retrospective Studies;
Survival Rate
- From:Cancer Research and Treatment
2005;37(5):268-272
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy. MATERIALS AND METHODS: From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38 ~83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50~70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%). RESULTS: The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81). CONCLUSIONS: For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.
